The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GCT1021-01, a first-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-Axl-ADC) in patients with solid tumors (NCT02988817).
 
Ulrik Niels Lassen
No Relationships to Disclose
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Merck; Novartis
Travel, Accommodations, Expenses - AstraZeneca; EMD Serono; Pfizer
 
Juanita Suzanne Lopez
No Relationships to Disclose
 
R Donald Harvey
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; HERON; Takeda
Research Funding - Agensys (Inst); Amgen (Inst); ArQule (Inst); AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Cleave Biosciences (Inst); Eisai (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Takeda
 
Malaka Ameratunga
No Relationships to Disclose
 
Jan de Hoon
Consulting or Advisory Role - Amgen Astellas BioPharma; Galderma; Merck Sharp & Dohme
Research Funding - Amgen Astellas BioPharma
 
Nedjad Losic
Employment - Genmab
Leadership - Genmab
Stock and Other Ownership Interests - Genmab
Honoraria - Genmab
 
Steen Lisby
Employment - Genmab
Leadership - Genmab
Stock and Other Ownership Interests - Genmab
Honoraria - Genmab
 
Ulf Forssmann
Employment - Genmab
Stock and Other Ownership Interests - Genmab
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Biogen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Fresenius (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hampton Medical Conferences (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Kendle (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Quintiles (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst); Sigma-Tau (Inst); Telik (Inst); TRM Oncology (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Proacta (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche